IL-2对免疫激活和免疫耐受的双向调节作用

被引：166

作者：

翟志敏 ^{[1
,2
]}

机构：

[1] 安徽医科大学第二附属医院血液科生物医疗研究中心

[2] 安徽医科大学血液病研究中心

来源：

中国药理学通报 | 2013年 / 29卷 / 03期

关键词：

白细胞介素2; 受体; 免疫激活; 免疫耐受; 调节性T细胞; 效应性T细胞;

D O I：

暂无

中图分类号：

R392.1 [免疫生物学];

学科分类号：

100108 [医学免疫学];

摘要：

白细胞介素2(interleukin-2,IL-2)从被发现迄今已有30余年,但仍然是最受关注和被广泛研究的细胞因子之一。IL-2最初是从T细胞培养上清液中分离获得,并对体外培养的T细胞具有促进增殖作用,因此传统认为IL-2是一种激活T细胞,并维持T细胞分化和增殖的T细胞生长因子,同时也参与炎症或自身免疫性反应。近年来,人们在IL-2或IL-2R缺陷小鼠动物模型等的研究中发现IL-2的主要功能不仅是提升免疫反应,更重要的是维持Treg细胞的稳定及其介导的免疫耐受,故具有双向免疫调节作用,这些对IL-2生物学活性的新发现,也促使人们开始重新评价和认识临床使用IL-2的疗效、适应症和给药方式。

引用

页码：319 / 322

页数：4

共 10 条

[1]

Mast Cell Interleukin-2 Production Contributes to Suppression of Chronic Allergic Dermatitis [J].

Hershko, Alon Y. ;

Suzuki, Ryo ;

Charles, Nicolas ;

Alvarez-Errico, Damiana ;

Sargent, Jennifer L. ;

Laurence, Arian ;

Rivera, Juan .

IMMUNITY, 2011, 35 (04) :562-571

[2]

CS02-4. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages.[J].Wei Liao;Jian-Xin Lin;Lu Wang;Peng Li;Warren J Leonard.Cytokine.2011, 1

[3]

Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity [J].

Malek, Thomas R. ;

Castro, Iris .

IMMUNITY, 2010, 33 (02) :153-165

[4]

Interleukin-2 and Inflammation Induce Distinct Transcriptional Programs that Promote the Differentiation of Effector Cytolytic T Cells [J].

Pipkin, Matthew E. ;

Sacks, Jilian A. ;

Cruz-Guilloty, Fernando ;

Lichtenheld, Mathias G. ;

Bevan, Michael J. ;

Rao, Anjana .

IMMUNITY, 2010, 32 (01) :79-90

[5]

IL-2 and its high-affinity receptor: Genetic control of immunoregulation and autoimmunity [J].

Wang, Jinguo ;

Wicker, Linda S. ;

Santamaria, Pere .

SEMINARS IN IMMUNOLOGY, 2009, 21 (06) :363-371

[6]

Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer [J].

Lemoine, Francois M. ;

Cherai, Mustapha ;

Giverne, Camille ;

Dimitri, Dalia ;

Rosenzwajg, Michelle ;

Trebeden-Negre, Helene ;

Chaput, Nathalie ;

Barrou, Benoit ;

Thioun, Nicolas ;

Gattegnio, Bernard ;

Selles, Frederic ;

Six, Alain ;

Azar, Nabih ;

Lotz, Jean Pierre ;

Buzyn, Agnes ;

Sibony, Mathilde ;

Delcourt, Annick ;

Boyer, Olivier ;

Herson, Serge ;

Klatzmann, David ;

Lacave, Roger .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2009, 35 (03) :569-581

[7]

High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma.[J].Jacob A.Klapper;Stephanie G.Downey;Franz O.Smith;James C.Yang;Marybeth S.Hughes;Udai S.Kammula;Richard M.Sherry;Richard E.Royal;Seth M.Steinberg;StevenRosenberg.Cancer.2008, 2

[8]

Overview of interleukin-2 function, production and clinical applications [J].

Gaffen, SL ;

Liu, KD .

CYTOKINE, 2004, 28 (03) :109-123

[9]

Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment.[J].Dennis M. Willerford;Jianzhu Chen;Judith A. Ferry;Laurie Davidson;Averil Ma;Frederick W. Alt.Immunity.1995, 4

[10]

THE IMMUNOTHERAPY OF HUMAN CANCER WITH INTERLEUKIN-2 - PRESENT STATUS AND FUTURE-DIRECTIONS [J].

KOLITZ, JE ;

MERTELSMANN, R .

CANCER INVESTIGATION, 1991, 9 (05) :529-542

← 1 →